Form 4: Cormorant Asset Management Reduces Corbus Pharma Stake

Cormorant Asset Management and related entities reported the sale of 30,029 shares of Corbus Pharmaceuticals Holdings, Inc. common stock.

Summary

• Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, and Bihua Chen reported a change in beneficial ownership of Corbus Pharmaceuticals Holdings, Inc. (CRBP) common stock.
• The transaction involved the disposition of 30,029 shares of common stock.
• The shares were sold on December 11, 2025, at a weighted average price of $11.456 per share.
• The sale price ranged from $11.20 to $12.15 per share in a series of open market transactions.
• Following the reported transaction, the reporting persons beneficially own 2,344,971 shares of common stock indirectly.
• Cormorant Asset Management, LP serves as the investment manager of Cormorant Global Healthcare Master Fund, LP.
• Bihua Chen serves as the managing member of Cormorant Asset Management, LP, Cormorant Global Healthcare GP, LLC, and the Master Fund.
• All reporting persons disclaim beneficial ownership of the shares except to the extent of their pecuniary interest.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant institutional investor (10% owner) reducing its stake in the company, which can signal decreased confidence or a strategic shift.

Negatives

• A significant shareholder, Cormorant Asset Management (a 10% owner), reduced its stake in Corbus Pharmaceuticals Holdings, Inc. by selling 30,029 shares.
• Such a sale by a major investor can be interpreted by the market as a lack of confidence or a strategic shift away from the company.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The transaction involves the sale of shares by Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, and Bihua Chen, who are considered related parties due to their significant ownership (10% owner) and management roles in the investment entities.

Stakeholder Impact

• Shareholders may react negatively to the news of a major institutional investor reducing its stake, potentially leading to downward pressure on the stock price.
• The transaction could influence investor sentiment and perception of the company's future prospects.

Key Dates

Recommendation

The sale of shares by a 10% owner, Cormorant Asset Management, is a bearish signal. Such a move by a significant institutional investor often indicates a loss of conviction in the company's future performance or a strategic decision to reallocate capital, which could lead to negative market sentiment and potential share price decline.

Keywords

Corbus Pharmaceuticals, CRBP, Cormorant Asset Management, Insider Trading, Form 4, Stock Sale, Beneficial Ownership, Healthcare Investment